UCLA Magnesium Formulation Athlete Study
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-35
SponsorUniversity of California, Los Angeles
About this trial
This randomized, double-blind, placebo-controlled trial will compare magnesium glycinate, magnesium L-threonate, and placebo in UCLA varsity athletes. Participants will complete a baseline monitoring period followed by 4 weeks of blinded nightly supplementation. WHOOP or study-approved wearable data will be used to evaluate sleep efficiency, total sleep time, sleep consistency, heart rate variability, resting heart rate, and recovery metrics. Baseline and final testing will assess selected reaction and physical performance outcomes. The primary outcome is change in WHOOP-derived sleep efficiency from baseline week to final treatment week.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Age 18 to 35 years.
Current UCLA varsity athlete.
Actively training or competing during the study period.
Willing to wear WHOOP or a study-approved wearable device continuously during baseline and treatment periods if wearable data are used.
Disqualifiers
Current magnesium supplementation without completion of an appropriate washout before baseline.
Current investigational drug or investigational supplement use.
Current use of prescription or over-the-counter sleep medications unless reviewed and permitted by the study clinician.
Diagnosed sleep disorder that, in the investigator's judgment, would confound outcomes or increase risk.
Trial design
Design model
Parallel
Treatments tested in this trial
Magnesium glycinate
Dietary supplementBlinded oral magnesium glycinate capsules taken nightly for 28 days.
Magnesium L-threonate
Dietary supplementBlinded oral magnesium L-threonate capsules taken nightly for 28 days.
Placebo
Other interventionMatching placebo capsules taken nightly for 28 days.
Treatment groups
150 Participants
are divided into 3 treatment groupsGroup A: Magnesium GlycinateExperimental treatment 1 intervention
Group B: Magnesium L-ThreonateExperimental treatment 1 intervention
Group C: PlaceboPlacebo comparator 1 intervention
Trial outcomes
Primary outcomes
1
Change in WHOOP-derived sleep efficiency percentage from baseline week to final treatment week
Average nightly WHOOP-derived sleep efficiency, expressed as a percentage, will be calculated for the baseline week and final treatment week. A valid week requires at least 5 usable nights in the 7-day window. The outcome is final-treatment-week average minus baseline-week average; higher values indicate improved sleep efficiency.
Time frame
Baseline week to final treatment week, approximately 5 weeks total including baseline monitoringSecondary outcomes
1
Change in BlazePod RIW Challenge reaction time in milliseconds from baseline to final visit
Reaction performance will be measured using the prespecified BlazePod RIW Challenge protocol. The outcome is change in reaction time in milliseconds from baseline to final visit. Lower reaction time indicates better performance.
Time frame
Baseline to final visit, approximately 5 weeks2
Change in BlazePod Speed Tap reaction time in milliseconds from baseline to final visit
Reaction performance will be measured using the prespecified BlazePod Speed Tap protocol. The outcome is change in reaction time in milliseconds from baseline to final visit. Lower reaction time indicates better performance.
Time frame
Baseline to final visit, approximately 5 weeks3
Change in WHOOP-derived sleep consistency score from baseline week to final treatment week
WHOOP-derived sleep consistency score, or an equivalent prespecified wearable-derived sleep timing regularity metric, will be summarized for the baseline week and final treatment week. The outcome is final-treatment-week average minus baseline-week average.
Time frame
Baseline week to final treatment week, approximately 5 weeks total including baseline monitoring4
Change in WHOOP-derived total sleep time in minutes from baseline week to final treatment week
Average nightly total sleep time captured by WHOOP, expressed in minutes, will be calculated for the baseline week and final treatment week. The outcome is final-treatment-week average minus baseline-week average.
Time frame
Baseline week to final treatment week, approximately 5 weeks total including baseline monitoringSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: